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The granting of clinical staff privileges to physicians is one of 
the primary mechanisms used by institutions to uphold the 
quality of care. The Joint Commission on Accreditation of 
Healthcare Organizations requires that the granting of i~~tiai 
or continuing medical staff privileges be based on assess- 
ments of applicants against professional criteria that are 
specified in the medical st,aff bylaws. Physicians themselves 
are thus charged with identifying the criteria that constitute 
professional completence and with evaluating their peers 
accordingly. But the process of evaluating a physician’s 
knowledge and competence is often constrained by the 
evaluator’s own knowledge and ability to elicit the appropri- 
ate information, a problem that is compounded by the 
growing number of highly specialized procedures for which 
privileges are requested. 
This guideline is one of a series developed by the American 
College of Physicians, the American College of Cardiology, 
and the American Heart Association to assist in the assess- 
ment of physician competence on a procedure-specific basis. 
The minimum education, training, experience, and cognitive 
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and technical skills necessary for the competent performance 
of percutaneous tra~s~~lrni~~ c~Jrooary angioplasty (PTCA) 
are specified; when er possible, these are base 
lished data :in~i~g t se factors with corn 
procedures or, in the absence of such data, on consensus of 
expert opinion. They are applicable to any practice setting 
and can accommodate a number of ways physicians might 
s~bs~~tiate competence in the performance of specific pro- 
cedures. No attempt has been made to establish requirements 
for the use of newer interventional devices such as lasers, 
atherectomy catheters, or rotational devices.. Credentials 
committees of individual hospitals may need to develop their 
own criteria in consultation with appropriate experts for 
authorizing the use of these and other new procedures. 
e 
PTCA was introduced into clinical practice in 1977 (I) as 
an alternative form of revascularizalion of the ischemic 
myocardium; it thus constitutes a relatively new form of 
therapy. However, it has gained wide clinical acceptance, 
and there is currently an extraordinary expansion of its use, 
with an estimated 234,000 procedures performed in the 
United States in 1988. Such growth is attributed not on!y tc 
demonstrated clinikl benefit but also to recent technical 
advances that have led to improved techniques and higher 
success rates. 
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pTCA was first used predominantly to treat patients with 
discrete, proximal, noncalcified subtotal occlusive lesions in 
a single coronary artery. In subsequent years, the technique 
has been applied successfully to patients with mUkivCSd 
disease, multiple subtotal stenoses in the same vessel., recent 
accessible complete occlusions, partial occlusion of saphen- 
ous vein or internal mammary artery grafts, and recent 
thrombotic occlusions in acute myocardial infarction. 
Like coronary artery bypass surgery, the alternate 
method of myocardial revascularization, the leading indica- 
tion for PTCA is the relief of angina. It is also recognized 
that the procedure entails definite risks comparable to those 
of coronary artery bypass surgery, including a procedural 
mortality of approximately 1% and a nonfatal myocardial 
infarction rate in the range of 4.5% in elective cases (2). 
After a decade of experience, it is now reasonable to expect 
an overall success rate of >85% for single lesion balloon 
dilations within any program. In addition to operator skill 
and experience, procedural success relates to certain patient 
characteristics and, very importantly, to angiographic char- 
acteristics of the lesion or lesions to be dilated. Inherent to 
the strategy of coronary angioplasty is the realization that, in 
addition to the 5-i5% of cases in which the balloon fails to 
properly engage a lesion, 3-6% of patients will require 
urgent surgery to bypass a coronary artery occluded during 
the procedure. For this reason, there is general agreement 
that an experienced cardiovascular surgical team must be 
available within the institution for emergency surgery for all 
angloplasty procedures (3). 
There is similar consensus that rigorous, valid peer re- 
view must be established within each institution for critical 
evaluation of the success, failure, and complication rates of 
physicians performing FTCA within that institution (3). The 
surgical profession has provided a working modd for ad- 
dressing these and similar issues with regularly scheduled 
conferences to review the indications for procedures and 
their mortality and morbidity rates. Attendance require- 
ments are designed to assure impartial peer review. 
For the purpose of this document, performing a PTCA 
includes understanding the indications for and contraindica- 
tions to the procedure, preprocedural evaluation, perfor- 
mance of the procedure, recognizing and managing compli- 
cations, and postangioplasty management. The latter 
includes both care immediately after the procedure, with 
attention directed to monitoring for evidence of’ recurrent 
ischemia and to assure appropriate hemostasis at the site of 
catheter insertion, and the longer term evaluation of the 
patient for recurrent ischemia. 
Some inherent limitations of PTCA include abrupt vessel 
closuW inCOmpkte revascuiarization, and restenosis. Be- 
cause PTCA is being used in more complex clinical and 
pathoanatomic situations, there is an awareness that in some 
Patients, revascuhUizat!on is “incomplete” with a less than 
optimal correction of their pathophysiological state. Jn pa- 
tients with multivessel disease, only experienced judgment 
can discern whether to attempt dilation of all accessible, 
significant lesions or to approach only the lesion deemed 
most likely to cause myocardial Lchemia. 
Although the initial outcome for coronary angioplasty 
procedures has improved progressively over the past 18 
years, the incidence of restenosis over the first 3-6 months 
after dilation remains unchanged at approximately 30%. 
There are recognized patient and procedural characteristics 
that are associated with restenosis. 
The competent performance of PTCA requires not only a 
complete knowledge base and technical skills but also sound 
clinical judgment based on specific experience. Knowledge 
of the anatomy, physiology, and pathology of the coronary 
circulation and a thorough understanding of ventricular 
physiology are required for the proper application of this 
technology to patient management. In addition to manual 
dexterity, an operator is required to have extensive expe& 
ence with the technique of cardiac catheterization aPd 
coronary arteriography to do this procedure safely and we!#l. 
Moreover, because of the risks and serious consequences of 
a failed procedure, immediate identification of complications 
and appropriate management, often requiring broad institu- 
tional support, remain the primary obligation of the physh- 
cian undertaking PTCA and require critical cognitive and 
technical skills, These skills are the most significant compo- 
nents to be evaluated in assessing physician competence in 
PTCA. 
The training required for competence in the performance of 
PTCA is in accord with the recommendations of the ;imerican 
College of Cardiology 17th Bethesda Conference on Adult 
Cardiology Training (4) and “Guidelines for Credentialing and 
Facilities for Performance of Coronary Angioplasty” from the 
Committee on Interventional Cardiology of the Society for 
Cardiac Angiography and Interventions (5). The indications, 
contraindications, and guidelines for the performance of PTCA 
in the clinical setting are derived principally from the Sobcom- 
mittee Report on PTCA of the American College of Cardiology/ 
American Heart Association Task Force on Assessment of 
Diagnostic and Therapeutic Cardiovascdar Procedures (3). 
Physicians who perform PTCA must understand the 
indications for and contraindications to the procedure. The 
approach to every angioplasty procedure requires a knowl- 
edgeable judgment that weighs the likelihood of a successful 
procedure against the likelihood of failure and the risk of 
complications that include aLupt vessel closure, morbidity, 
and mortality. Indications for a given procedure will vary 
according to anatomic (single vs. multivessel db.:ase), clin- 
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1. Characteristics of Type A , and C Lesions ~nfl~~~ci~g 
t-cutaneous Translum Coronary Angioplasty (3) 
Type A lesions (high S~CE~SS, X5%: low risk) 
Discrete (<IO mm length) Little or no calcification 
Concentric Less than totally occlusive 
Readily accessible Not ostial in location 
Nonangulated segment No major branch 
(445”) involvement 
Smooth contour Absence of thrombus 
Type B lesions (moderate success, 60-8596; moderate risk)* 
Tubular (IQ-20 mm long) Moderate to heavy 
Ca;CifiCaiidn 
Eccentric Total occlusions <3 months 
ok! 
Moderate tortuosity of Ostial location 
proximai segment 
Moderately angulated segment Bifurcation lesions requiring 
(>45” but <90”) double guide wires 
Irregular contour Some thrombus present 
Type C lesions (low success, GO%; high risk1 
Diise (>20 mm length) Total occlusion >3 months 
old 
Excessive tcrtuosiry of inability to protect major 
proximal segment side branches 
Extremely angulated segments Degenerated veir! grafts with 
(>W) friable lesions 
*Although the risk of abrupt vessel closure is moderate, in certain 
instances the likelihood of a major complication may be low, such as in 
dilation of total occlusions <3 months o!d or when abundant collateral 
channels supply the distal vessel. 
ical (asymptomatic vs. symptomatic patients), and 
logic21 (presence or absence of inducible ischemia) consid- 
erations. Most impo~ant~y, the indications for angioplasty 
are based primarily on a multifactorial risk assessment 
weighed against expected outcome. 
In identifying the indications for PTCA, the Subcommit- 
tee Report on PTCA of the American College of Cardiology/ 
American Heart Association Task Force on Assessment of 
Diagnostic and Therapeutic Cardiovascular Procedures pro- 
posed three classes of indications: Class 1 comprises condi- 
tions for which there is general agreement that PTCA is 
justified; Class II comprises conditions for which PTCA is 
performed but where there is divergence of opinion with 
respect to its justification in terms of value and appropriate- 
ness; and Class 111 comprises con9tions for which there is 
general agreement that PTCA is not ordinarily indicated (3). 
Additionally, the Task Force recognized the uniquely 
technical aspects of PTCA and proposed a lesion-specific 
classification of angiographic patterns as a guide for estimat- 
ing the likelihood of a successful procedure as we!L as the 
likelihood of developin: abrupt vessel closure (3). Table 1 
lists lesion-specific C;htii ~~~iaril;iics according to three types 
of lesions: Type A &ons have those characteristics that 
allow an anticipated success rate of >85% and have a low 
For path& who haVe a S~g~~~Ca~t lesion in one or more major epicardial 
arteries that subtend at least a moderate-sized area of viable myocardium 
and who: 
1. Have recurrent ischemic episodes after myocardial infarction 
2. Show evidence of myocardial ischemia while on medical therapy during 
laboratory testing (including electrocardiographic monitoring at rest, as 
with unstable angina) 
3. Have angina pectorir that has not responded adequately to medical 
treatment 
ave been resuscitated from cardiac arrest or sustained ventricular 
tachycardia in the absence of acute myocardial infarction 
5. Must undergo high-risk noncardiac surgery, if angina is present or there 
is objective evidence of ischemia 
*For a complete listing and discussion of accepted indications for PTCA 
see Reference 3. 
t vessel closure. Type 
characteristics that result in a lower than optimal success 
% or have a moderate risk o 
Type C lesions have those 
teristics that result m an ~~acce~tab~y low success rate 
(<60%) or that have a high risk of abrupt vessel closure, or 
both. As such, Type C lesions are not considered suitable for 
PTCA. 
This approach is ~~r~e~tiy useful, and a complete listing 
discussion of the presently accepted indications for 
A appears in “guidelines for rcutaneous Tra~.~~umi- 
candidates must have si ions in one or more 
major epicardial arteries us-ally subtending large areas of 
viable myocardium, with convincing evidence of myocardial 
ischemia. In the optimal candidate the likelihood of a suc- 
cessful dilation is expected to be >$5% with a likelihood of 
abrupt vessel closure <4%, and a. mortality rate of 0.5%. 
Although there are clinical cond:ll:ions that may justify a 
lower tolerance for th’e risk of ab’nupt vessel closure, there 
should be no compromise on the risk for significant mortality 
and morbidity. 
The role of PTCA in the management of patients during 
the course of an acute myocardial infarction is cutrently the 
subject of intense investigation. Evidence suggests that the 
role for PTCA in this setting may be less than anticipated. 
Recently, three large randomized clinical triak have all 
concluded that PTCA routinely performec immediately after 
thromboiytic therapy (tissue plasminogen activator) not only 
fails to improve ventricular function or reduce reocclusion 
rates but can also be detrimental to the patient because off 
increased hemorrhagic complications (6,7,8). A fourth study 
also failed to sho’u any improvement in ventricular function 
or recurrent infarction rates by routine performance of 
PTCA 18-48 hours after thrombolylic therapy (9). 
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Table 3. Selected Contraindications to krCUtaneOUS Tmnsluminal Table 4. Untoward Events Related to Elective Percutaneous 
Coronary Angioplasty Transluminal Coronary Angioplasty* 
Absolute 
Left main obstructions 
Severe, diffuse 
disease, extensively 
spread throughout the 
involved vgrssels 
Relative 
Stenosis ~50% (by direct measurement) 
Noninfarct related lesions at time of 
acute infarction angioplasty 
Event Frequency (Q) 
Death 
Nonfatal myocardial infarction 
Emergency coronary artery bypass surgery 
Restenosis within 3-6 months 
I 
4.3 
3.5 
25-M 
No accredited 
institutional cardiac 
surgery mmm 
AbNpt VeSSd CIOSUI% 
would :esult in 
cardiogenic shock 
Variant angina 
No evidence of myocardial ischemia 
Anticipated success rate G@% (Type C 
lesions) 
*From the NHLBl Registry.* 
The major complications related to elective coronary 
angioplasty as reported in the National Heart, Lung, and 
Although there is evidence that the procedure can be used 
effectively as the primary intervention (i.e., without throm- 
bolysis) for establish+ reperfusion in the very early hours 
of an evolving infarctior., many important questions remain. 
These include the impact of procedural delay required for 
PTCA, the influence of thrombus on abrupt vessel closure, 
and subsequent restenosis rates. The optimal timing and 
long-term benefit of PTCA in the management of patients 
with acute infarction are questions that must await further 
data from ongoing investigations. 
Blood Institute registry are listed in Table 4. Patients under- 
going PTCA are at a risk for the same potential complica- 
tions that are associated with diagnostic cardiac cathieteriza- 
tion, including arterial or venous obstructions, vessel 
perforations, bleeding, hypersensitivity reactions, anld infec- 
tion. Myocardial infarction, stroke, and death can also occur 
as a result of cardiac catheterization but are infrequent. 
The generally accepted contraindications to the perfor- 
mance of PTCA are listed in Table 3. The presenck%f a 
significant lesion in the left main coronary artery is viewed as 
an absolute contraindication for ballnon dilation unles!; this 
main segment is protected by at least one completely patent 
bypass graft to the left coronary circulation. The absence of 
an accredited cardiac surgical program within the institution 
is also viewed as an absolute contraindication to perfor- 
mance of the procedure. The importance of a relative 
contraindication to angioplasty will vary with the sympto- 
matic state and the general medical condition of the individ- 
ual patient. For example, certain risks may be appropriate in 
severely symptomatic individuals who are noit candidates for 
bypass surgery, whereas these risks would be inadvisable for 
an asymptomatic or mildly symptomatic individual. Clearly, 
because a procedure can be performed does not mean that it 
should be performed. Such would be the case, for example, 
for the patient who has advanced comorbidity, marked 
depression of left ventricular contractile function, and an- 
oxic encephalopathy at the time of presentation with recur- 
rent infarction. 
It should be clear that not all angioplasty procedures can 
be undertaken with the assumption that procedural mortality 
is 1%. When used as the primary intervention to establish 
reperfusion in the setting of acute myocardial infarction, for 
example, the mortality rate ranges from 5-20% in successful 
cases and is higher than 35% when the angiopiasty is unsuccess- 
ful (l&11). 
Training must result in the acquisition of both the cogni- 
tive and technical skills outlined in Tables 5 and 6. As 
indicated by several organized bodies within the field of 
cardiology (3-5), trainees should complete a full cardiovas- 
cular training program that meets the requirements of the 
Table 5. Cognitive Skills Needed to Perform Percutaneous 
Transluminal Coronary Angioplasty Competently 
Knowledge of GUI rent indications for the procedure and likelihood of 
success in individual cases (Class I, II. and II!) 
Knowledge of contraindications to the procedure 
Knowledge of preprocedural evaluation, including reasons for selecting 
percutaneous transluminal coronary angioplasty over potentia! alternatives 
(i.e., coronary artery bypass surgery: medical therapy alone) 
Knowledge of the anatomy, normal physiology, and pathophysiology of the 
coronary circulinion 
These examples of common indications and contraindi- 
cations, which were considered important when these guide- 
lines were developed, outline the range of cognitive material 
that the applicant should master. Such a list may be modified by 
clinical judgment in individual patients and by advances in 
medical practice. 
Knowledge of venlricular physiology 
Ability iir recognize complications of cardiac catheterization and 
perculaneous translumina! coronary angioplasty promptly 
Knowledge of and experience in the management of complications 
Ability tc communicate the risk, benefits, and results of the procedure to 
the pat&t, to the medical record, and 10 others involved in the care of the 
pMien1 so that appropriate informed consent can be obtained 
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TabPe 6. Technical Skills Needed to Perform Percutaneous 
Transluminal Coronary ~~gi~~~asty ~~~~e~e~t~y 
Manual dexterity 
Operational skill in the use of x-ray, video, and other required equipment 
Seasoned experience with cardiac catherization, coronary arteriography, 
and radiation safety 
Additional demonstrated competence in percutaneous transluminal 
coronary angioplasty (see text) 
Technical aspects of management of complications of percutaneous 
transluminal coronary angioplasty 
Demonstration of continued technical competence in 6he procedure over time 
icine for cert~~catio~ in 
e and conforms to the ~u~de~~~es out- 
College of Cardiology 17t 
Conference on Adult Cardiology Training. The 
ilukde intensive and extensive 
t~~~~te~~zat~o~ and coronary angio- 
require a minimum of I2 mom 
ardiac catheterization I 
The trainee should have participated in or pe 
ary angiographic procedures, with 
as the primary operator. To 
mance of PTCA, an additional 1 year of fo 
structured fellowship progr,am devoted to 
mended (3-5). During this time, a miRim~m of 125 coronary 
anginplasty procedures, including 75 performed as the pri- 
mary operator, should be documented to attain competence 
in the procedure. Certification of a candidate’s experience 
and competence should be substantiated by the supervisor 
or director of the training program and be documented in a 
procedural log book. 
Prior training in cardiology ma!y not have included spe- 
cific experienee with PTCA but may have provided overall 
experience in cardiology that should contribute to eventual 
competence in this procedure. Nevertheless, lack of the 
above experience with FICA during fellowship training 
precludes competence in it at completion. Alternate methods 
of certification may be used for experienced angiographers 
who have not completed a formal fellowship training pro- 
gram in coronary angioplasty. Such individuals should meet 
the following requirements: 
1. A minimum of 2 years of expeGence in performing 
cardiac catheterization without supervision. This experience 
should include a minimum of 5O0 diagnostic cardiac cathe- 
terization and coronary angiographic procedures with docu- 
mentation of complication rates that are within accepted 
guidelines and with certification of competence in recogni- 
tion and management of serious cardiovascular complica- 
colleague with recognizes competence, and 
2. Special ~~s~~~ctio~ in coronary a~~~o~~asty 
rimary operator, under the 
oc~memtation of expe- 
rience should be provided ook with the results to be 
under whom tke candidate trained. For such experience 
ained before 1989, doc~me~tatio~ ay be certified only by 
ator. For newly certifie operators this case load should be 
ved within 18 mon s of receiving hospital 
Pasty. if the physici 
mance volume or procedure results (success and comphca- 
tion rates) do not meet established standards, a probationary 
period of closer surv llance by a recognized expert should 
be insti!uted. Since indications for angioplasty and the 
technology relating to the procedure are rapidly changing, 
documentation of ~o~ti~~~i~g education in interventional 
techniques is necessary. Participation in formal instruction 
of 30 hours at least every 2 years is recommended. 
Competence in PTCA may be difkult to define, but it is 
agreed that operator skill and judgment are greatly inilu- 
enced by personal experience (both past and present) and by 
the environment in which the operator practices. Interaction 
between colleagues performing similar procedures within the 
same institution is decidedly more valuable than one indi- 
vidual performing all the procedures, in isolation, as the sole 
expert. Thus, it may be desirable to consider these factors 
when assessing anraual caseloads necessary for maintaining 
competence in individuals who perform somewhat under 75 
cases per year (but no less than 50 cases per year). Clne 
method proposed as an alternative to the more absolute 
requirement of 75 PTCA procedures per year performed as 
the primary operator suggests a value credit both for the 
number of cases performed as primary operator during the 
previous 3 years as well as the institutional volume per year. 
As an example, such an approach might use a formula like 
I;ngio$asty volume rating = X t 0.2Y t 0.32 
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where X is cases as primary operator during the current 
year, Y is cases per year at the institution, and Z is cases as 
primary operator during the previous 3 years. 
The following rating scale would be used: < 150, unac- 
ceptable; 150-170, needs improvement; and >170, ade- 
quate . 
The results of FWAs performed by all individuals at an 
institution must be evaluated by a valid peer review mech- 
anism that is required as an ongoing process within each 
institution offering coronary angioplasty as part of its health 
care program. Although institutional review can take many 
forms and will vary according to such factors as the size of 
institutions and departments, the number of staff and the 
volume of procedures, there are basic requirements to 
assure a meaningful review. At a minimum, the opportunity 
must exist for physicians, including those not performing 
PTCAs but knowledgeable about the procedure, to review 
the overall results of the program on a regular basis. In 
addition, attention should be directed to the success and 
failure rates of individual operators, their complications 
(including emergency surgical procedures), and mortality 
rates. Institutions with medical or surgical groups. or both, 
that cannot adequately meet this obligation should tindertake 
regional review with cooperating institutions or terminate 
their program in angioplasty. 
Maintenance of competence is important not only for 
physicians performing PTCA but also for the institution 
offering the service. A significant volume of cases per 
institution is essential for the maintenance of assured quality 
and safe care. To maintain these goals, an institution should 
perform at least 200 PTCA procedures annually; otherwise it 
should not offer, or should consider discontinuing, angio- 
9lastY as part of its health care program. Exceptions to this 
volume minimum must be based on the documentation of 
high quality performance of appropriate procedures within 
the institution. 
In the present climate of intense economic pressures, it 
should be clear that not every institution anxious to offer 
angioplasty as part of its health care program can be allowed 
to do so. Similarly, not every cardiologist desiring to per- 
form angioplasty shou!d perform the procedure. credentials 
to perform angioplasty in hospitals should be limited to those 
physicians with appropriate training and demonstrated com- 
petence. 
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